Enzo Biochem Inc. (NYSE:ENZ), as part of its continuing program to offer novel molecular tests, announced that its Enzo Clinical Labs subsidiary has reached an agreement with IncellDx Inc. of Menlo Park, CA, for the rights to market a proprietary laboratory test. The test is based upon HPV OncoTect™, an advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer and will further expand Enzo’s approach to providing comprehensive clinical information to physicians for managing diseases associated with women’s health. Upon receiving the appropriate approvals, Enzo will become the first New York licensed reference laboratory to offer the test.
HPV OncoTect™ is a novel method for screening for the likelihood of progression to cervical carcinoma by measuring potential oncogenic activity of the human papillomavirus (HPV) in infected cervical cells. The assay functions by detecting and quantifying the expression of viral oncogenes responsible for triggering progression to cervical cancer, thus improving the specificity that existing tests lack. As with other assays developed at Enzo Clinical Labs, HPV OncoTect™ will be validated during in-house studies prior to seeking New York State approval under a “LDT” regulatory pathway. Favorable reimbursement already exists for this type of testing.
“The HPV OncoTect™ technology is a flow-cytometry based method that can be used to identify the genetic expression of HPV that has already integrated into the cell, offering a better indicator of serious HPV infections than can be accomplished by identifying the presence of the virus alone,” said Dr. Robert Boorstein, MD, PhD., Medical Director of Enzo Clinical Labs. "This addition to our growing line of molecular diagnostic tests for women’s health underscores our expanding specialization in advanced clinical and diagnostic testing. We intend to use this test initially for patients who have been shown to be HPV positive by standard techniques”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV